{"id":"W2528229149","doi":"10.1093/annonc/mdw198.25","title":"O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Tolerability; Oncology; Internal medicine; Colorectal cancer; Clinical endpoint; Randomized controlled trial; Cancer; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009352028,0.001284755,0.001505999,0.0004563605,0.0002520927,0.0008876574,0.0006710319,0.0008410063,0.004307773],"category_scores_gemma":[0.0005799767,0.0004569229,0.001500982,0.0003948335,0.0006721606,0.0009504261,0.0003101087,0.002423527,0.0008970188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006441446,"about_ca_system_score_gemma":0.001036028,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001855855,"about_ca_topic_score_gemma":0.006868841,"domain_scores_codex":[0.9997533,0.00009218154,0.00001120014,0.00004381749,0.00002790681,0.00007161722],"domain_scores_gemma":[0.9997135,0.00004333449,0.00004461415,0.0000221094,0.00001900127,0.0001574739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6211856,0.04687976,0.006865292,0.001682808,0.003235534,0.0002741242,0.0003524819,0.005029189,0.03900098,0.0006740252,0.008732718,0.2660876],"study_design_scores_gemma":[0.5653493,0.3964508,0.01915604,0.0001036512,0.001448369,0.0005190477,0.0001717739,0.002195116,0.005433093,0.0003324582,0.008769567,0.00007069177],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888471,0.003965917,0.0004654705,0.0006477349,0.0001911433,0.0007717392,0.001166141,0.0001239159,0.003820687],"genre_scores_gemma":[0.9808568,0.00573327,0.001734903,0.001034268,0.0002073669,0.0007199697,0.003060642,0.00005485702,0.006597924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004307773,"threshold_uncertainty_score":0.01441097,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03433400072271076,"score_gpt":0.373598782940577,"score_spread":0.3392647822178663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}